1. Surgical exploration
Complete evaluation of the abdominal cavity to determine the extent of disease and calculate the peritoneal carcinomatosis index (PCI).
Combined treatment of cytoreductive surgery and heated intra-abdominal chemotherapy for the treatment of peritoneal carcinomatosis with curative intent.
CONTACT SPECIALISTNeed to speak with a specialist?
Schedule your consultation with a specialist
Dr. Torrent explains in detail which patients are candidates for HIPEC treatment and how this procedure can significantly improve the prognosis in cases of peritoneal carcinomatosis.
HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is a procedure that combines cytoreductive surgery with the direct application of heated chemotherapy inside the abdominal cavity. It is used to treat tumors that have spread to the peritoneum (peritoneal carcinomatosis).
The goal is to remove all visible tumor implants through surgery and then apply heated chemotherapy to destroy residual microscopic cancer cells. Hyperthermia (heat) enhances the penetration and effect of chemotherapeutic drugs in tumor tissue.
The HIPEC procedure is performed in the operating room under general anesthesia and consists of several phases:
Complete evaluation of the abdominal cavity to determine the extent of disease and calculate the peritoneal carcinomatosis index (PCI).
Removal of all visible tumor implants, including peritonectomies and resection of affected organs if necessary.
Perfusion of the abdominal cavity with chemotherapy heated to 41-43°C for 60-90 minutes, ensuring contact with all peritoneal surfaces.
Performing intestinal anastomoses and closing the abdominal cavity after draining the chemotherapy solution.
HIPEC is especially indicated for the following tumors with peritoneal involvement:
Mucinous appendicular tumors with peritoneal spread. This is the indication with the best results, achieving long-term survival rates above 80%.
Primary tumor of the peritoneum where HIPEC has demonstrated significant survival benefit when complete cytoreduction is achieved.
HIPEC has shown benefit in advanced ovarian cancer, especially in the context of interval surgery after neoadjuvant chemotherapy.
In selected cases of colorectal carcinomatosis with low tumor burden and favorable biology.
HIPEC offers unique advantages in the treatment of peritoneal carcinomatosis:
Chemotherapy is administered directly where the disease is located, reaching concentrations up to 20 times higher than systemic chemotherapy.
When applied locally, systemic side effects are fewer than with conventional intravenous chemotherapy.
Hyperthermia increases the penetration and effectiveness of chemotherapeutic drugs in tumor tissue.
In selected indications, HIPEC offers the possibility of cure in patients who previously only had palliative options.
At Quenet-Torrent Institute we have one of the largest national and international experiences in cytoreductive surgery and HIPEC. Our team has performed more than 300 HIPEC procedures with oncological results published in high-impact scientific journals.
We work in a multidisciplinary environment that includes medical oncologists, radiologists, specialized anesthesiologists, and nursing staff with specific training in this complex procedure.
Every physician at Quenet-Torrent Institute is a recognized expert in their field, committed to each patient's well-being.
Oncological Surgeon
View doctor"Internationally renowned surgeon, expert in gastrointestinal and hepatobiliary tumors. Recognized for his precision in highly difficult surgeries."
Oncological Surgeon
View doctor"Specialist in gynecological tumors and peritoneal carcinomatosis. A reference in complex and personalized oncological surgery."
The HIPEC procedure is used in the treatment of various pathologies with peritoneal involvement.
Comprehensive treatment of peritoneal tumor spread from various origins.
More informationEspecially indicated in advanced ovarian cancer with carcinomatosis.
More informationIn selected cases of colorectal carcinomatosis with favorable disease characteristics.
More informationAnswers to the most common questions about the HIPEC procedure.
HIPEC combines cytoreductive surgery with direct application of heated chemotherapy (41-43°C) inside the abdominal cavity to treat peritoneal carcinomatosis.
Pseudomyxoma peritonei, peritoneal mesothelioma, advanced ovarian cancer, and selected cases of colorectal carcinomatosis Thorough preoperative assessment is essential for correct patient selection.
HIPEC delivers chemotherapy directly where the disease is, reaching concentrations up to 20 times higher than systemic chemotherapy, with lower systemic toxicity.
The complete procedure — cytoreduction plus HIPEC — typically takes 6-12 hours depending on disease extent, with the HIPEC phase lasting an additional 30 to 90 minutes.
It is a major surgery with inherent risks, but experienced teams and international protocols significantly minimize complications. Mortality is below 1-2% in specialized.
Complete the form and schedule your appointment to speak directly with the surgeon.